InsiderSignal.AI

InsiderSignal.ai

TVTX - Travere Therapeutics, Inc.

Insider Sale by Dube Eric M (CEO)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

4 days ago, Dube Eric M, serving as CEO at Travere Therapeutics, Inc. (TVTX), sold 60,000 shares at $30.93 per share, for a total transaction value of $1,855,839.00. Following this transaction, Dube Eric M now holds 432,886 shares of TVTX.

This sale represents a 12.00% decrease in Dube Eric M's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Wednesday, April 1, 2026 and publicly disclosed via SEC Form 4 filing on Thursday, April 2, 2026, 1 day after the trade was made.

Travere Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Dube Eric M

CEO

Eric Dube, Ph.D. is the President and Chief Executive Officer of Travere Therapeutics, Inc., a position he has held since January 2019[[1]](https://pace.bio.org/speakers/eric-dube). He is a purpose-driven leader and rare cancer survivor who guides the company's mission to develop life-changing therapies for rare kidney diseases[[5]](https://travere.com/our-company/leadership-and-board/). Dube holds a B.S. from Santa Clara University and both an M.A. and Ph.D. from Cornell University[[1]](https://pace.bio.org/speakers/eric-dube). Prior to leading Travere, he served as Head of North America for ViiV Healthcare and held senior leadership roles at GlaxoSmithKline, including Senior Vice President and Head of the Global Respiratory Franchise and Senior Vice President of Respiratory Japan[[1]](https://pace.bio.org/speakers/eric-dube). Throughout his career, he has progressed through positions in strategy, planning, operations, oncology, and managed markets[[1]](https://pace.bio.org/speakers/eric-dube). Beyond his executive responsibilities, Dube is a vocal advocate for the LGBTQ+ community and the rare disease community[[3]](https://fortune.com/ranking/lgbtq-leaders/2024/eric-dube/)[[4]](https://www.biocom.org/lifelines/member-spotlight-travere-therapeutics/). He co-founded OUTBio San Diego, the largest group for LGBTQ biotech professionals in the region, and was named one of the "OUTstanding 100 LGBT+ Executives" by the *Financial Times* in 2022[[4]](https://www.biocom.org/lifelines/member-spotlight-travere-therapeutics/). Dube currently serves on the Board of Directors for the Biotechnology Innovation Organization (BIO) and for Reneo Pharmaceuticals, Inc.[[1]](https://pace.bio.org/speakers/eric-dube) His personal experience as a cancer survivor at age 30 solidified his commitment to the pharmaceutical industry and rare disease research, driving his belief that effective therapies must be developed for patients who currently have no treatment options[[3]](https://fortune.com/ranking/lgbtq-leaders/2024/eric-dube/)[[4]](https://www.biocom.org/lifelines/member-spotlight-travere-therapeutics/).

View full insider profile →

Trade Price

$30.93

Quantity

60,000

Total Value

$1,855,839.00

Shares Owned

432,886

Trade Date

Wednesday, April 1, 2026

4 days ago

SEC Filing Date

Thursday, April 2, 2026

Filed 1 day after trade

HEALTHCAREBIOTECHNOLOGY

About Travere Therapeutics, Inc.

Company Overview

No company information available
View news mentioning TVTX

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/5312654

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime